Plasma Calprotectin Level as a Potential Biomarker in Different Phases of Pediatric Hemato-Oncological Malignancies: A Pilot Study
نویسندگان
1 Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran - Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran - Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Department of Biostatistics and Epidemiology, Faculty of public health, Ahvaz Jundishapur university of medical sciences, Ahvaz, Iran - Department of Biostatistics and Epidemiology, Faculty of public health, Ahvaz Jundishapur university of medical sciences, Ahvaz, Iran
4 Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran - Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
5 Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran - Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
doi
10.18502/ijpho.v15i1.17277چکیده
Background: Calprotectin has been known as a biomarker for systemic inflammation, especially in autoimmune disorders. Inflammation is a process associated with malignant progression, and calprotectin is a potential prognostic biomarker in some hematologic malignancies. Our pilot study aimed to evaluate the plasma calprotectin level as a promising biomarker in the relapsed/refractory phase of pediatric ...
